| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyCellularComponent | small-subunit processome | 1.93e-04 | 76 | 31 | 3 | GO:0032040 | |
| GeneOntologyCellularComponent | preribosome | 6.35e-04 | 114 | 31 | 3 | GO:0030684 | |
| GeneOntologyCellularComponent | 90S preribosome | 8.43e-04 | 29 | 31 | 2 | GO:0030686 | |
| Domain | HMG_box | 8.30e-05 | 53 | 30 | 3 | PF00505 | |
| Domain | HMG_BOX_2 | 8.78e-05 | 54 | 30 | 3 | PS50118 | |
| Domain | HMG | 8.78e-05 | 54 | 30 | 3 | SM00398 | |
| Domain | - | 9.27e-05 | 55 | 30 | 3 | 1.10.30.10 | |
| Domain | HMG_box_dom | 1.53e-04 | 65 | 30 | 3 | IPR009071 | |
| Domain | RhoGAP | 4.44e-03 | 62 | 30 | 2 | SM00324 | |
| Domain | RhoGAP | 4.58e-03 | 63 | 30 | 2 | PF00620 | |
| Domain | RHOGAP | 4.73e-03 | 64 | 30 | 2 | PS50238 | |
| Domain | RhoGAP_dom | 4.73e-03 | 64 | 30 | 2 | IPR000198 | |
| Domain | - | 4.73e-03 | 64 | 30 | 2 | 1.10.555.10 | |
| Domain | - | 6.23e-03 | 746 | 30 | 5 | 3.40.50.300 | |
| Domain | Rho_GTPase_activation_prot | 8.76e-03 | 88 | 30 | 2 | IPR008936 | |
| Domain | P-loop_NTPase | 1.06e-02 | 848 | 30 | 5 | IPR027417 | |
| Pathway | REACTOME_RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL | 5.72e-05 | 60 | 18 | 3 | M27613 | |
| Pathway | BIOCARTA_D4GDI_PATHWAY | 1.01e-04 | 12 | 18 | 2 | M15513 | |
| Pathway | BIOCARTA_D4GDI_PATHWAY | 1.19e-04 | 13 | 18 | 2 | MM1380 | |
| Pubmed | The functional interactome of PYHIN immune regulators reveals IFIX is a sensor of viral DNA. | 2.06e-08 | 349 | 31 | 7 | 25665578 | |
| Pubmed | 5.75e-07 | 847 | 31 | 8 | 35850772 | ||
| Pubmed | 3.62e-06 | 1084 | 31 | 8 | 11544199 | ||
| Pubmed | 3.81e-06 | 483 | 31 | 6 | 36912080 | ||
| Pubmed | The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis. | 3.82e-06 | 759 | 31 | 7 | 35915203 | |
| Pubmed | The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. | 5.71e-06 | 807 | 31 | 7 | 22681889 | |
| Pubmed | ZBTB2 protein is a new partner of the Nucleosome Remodeling and Deacetylase (NuRD) complex. | 1.04e-05 | 330 | 31 | 5 | 33301849 | |
| Pubmed | 1.08e-05 | 333 | 31 | 5 | 36779763 | ||
| Pubmed | Jade-1S phosphorylation induced by CK1α contributes to cell cycle progression. | 1.72e-05 | 56 | 31 | 3 | 26919559 | |
| Pubmed | Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. | 1.82e-05 | 1353 | 31 | 8 | 29467282 | |
| Pubmed | The small-subunit processome is a ribosome assembly intermediate. | 2.15e-05 | 8 | 31 | 2 | 15590835 | |
| Pubmed | 2.34e-05 | 62 | 31 | 3 | 34516797 | ||
| Pubmed | 3.25e-05 | 419 | 31 | 5 | 15635413 | ||
| Pubmed | 3.45e-05 | 208 | 31 | 4 | 11790298 | ||
| Pubmed | 3.46e-05 | 713 | 31 | 6 | 29802200 | ||
| Pubmed | 3.76e-05 | 1497 | 31 | 8 | 31527615 | ||
| Pubmed | E3 ubiquitin ligase RNF123 targets lamin B1 and lamin-binding proteins. | 4.13e-05 | 736 | 31 | 6 | 29676528 | |
| Pubmed | Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes. | 9.56e-05 | 857 | 31 | 6 | 25609649 | |
| Pubmed | Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. | 9.72e-05 | 1257 | 31 | 7 | 36526897 | |
| Pubmed | Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains. | 1.01e-04 | 533 | 31 | 5 | 30554943 | |
| Pubmed | Identification of novel ARF binding proteins by two-hybrid screening. | 1.60e-04 | 21 | 31 | 2 | 16582619 | |
| Pubmed | The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers. | 1.72e-04 | 954 | 31 | 6 | 36373674 | |
| Pubmed | The in vivo Interaction Landscape of Histones H3.1 and H3.3. | 1.87e-04 | 608 | 31 | 5 | 36089195 | |
| Pubmed | MYC multimers shield stalled replication forks from RNA polymerase. | 2.09e-04 | 989 | 31 | 6 | 36424410 | |
| Pubmed | 2.09e-04 | 332 | 31 | 4 | 25693804 | ||
| Pubmed | 2.15e-04 | 1429 | 31 | 7 | 35140242 | ||
| Pubmed | 2.27e-04 | 1442 | 31 | 7 | 35575683 | ||
| Pubmed | 2.29e-04 | 340 | 31 | 4 | 29478914 | ||
| Pubmed | Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation. | 2.32e-04 | 134 | 31 | 3 | 28695742 | |
| Pubmed | 2.61e-04 | 653 | 31 | 5 | 22586326 | ||
| Pubmed | 2.64e-04 | 655 | 31 | 5 | 35819319 | ||
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | 3.38e-04 | 1082 | 31 | 6 | 38697112 | |
| Pubmed | 4.36e-04 | 403 | 31 | 4 | 35253629 | ||
| Pubmed | The cell proliferation antigen Ki-67 organises heterochromatin. | 4.65e-04 | 410 | 31 | 4 | 26949251 | |
| Pubmed | Receptor-mediated clustering of FIP200 bypasses the role of LC3 lipidation in autophagy. | 6.82e-04 | 454 | 31 | 4 | 33226137 | |
| Pubmed | FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells. | 8.85e-04 | 212 | 31 | 3 | 33462405 | |
| Interaction | ZNF2 interactions | 6.68e-06 | 80 | 31 | 4 | int:ZNF2 | |
| Interaction | MNDA interactions | 9.35e-06 | 188 | 31 | 5 | int:MNDA | |
| Interaction | MAGEB2 interactions | 1.32e-05 | 349 | 31 | 6 | int:MAGEB2 | |
| Interaction | MEN1 interactions | 1.66e-05 | 1029 | 31 | 9 | int:MEN1 | |
| Interaction | CENPA interactions | 2.04e-05 | 377 | 31 | 6 | int:CENPA | |
| Interaction | H2AB2 interactions | 2.12e-05 | 107 | 31 | 4 | int:H2AB2 | |
| Interaction | ZNF330 interactions | 5.23e-05 | 446 | 31 | 6 | int:ZNF330 | |
| Interaction | H2AB3 interactions | 5.42e-05 | 136 | 31 | 4 | int:H2AB3 | |
| Interaction | ZBTB2 interactions | 5.49e-05 | 450 | 31 | 6 | int:ZBTB2 | |
| Interaction | ANOS1 interactions | 6.59e-05 | 143 | 31 | 4 | int:ANOS1 | |
| Interaction | SNRNP70 interactions | 9.07e-05 | 984 | 31 | 8 | int:SNRNP70 | |
| Interaction | H1-1 interactions | 1.06e-04 | 507 | 31 | 6 | int:H1-1 | |
| Interaction | H2BC5 interactions | 1.39e-04 | 331 | 31 | 5 | int:H2BC5 | |
| Interaction | POLR1E interactions | 1.80e-04 | 350 | 31 | 5 | int:POLR1E | |
| Interaction | KRR1 interactions | 2.60e-04 | 379 | 31 | 5 | int:KRR1 | |
| Interaction | USP36 interactions | 2.63e-04 | 599 | 31 | 6 | int:USP36 | |
| Interaction | GRM2 interactions | 2.67e-04 | 381 | 31 | 5 | int:GRM2 | |
| Interaction | BET1 interactions | 2.80e-04 | 385 | 31 | 5 | int:BET1 | |
| Interaction | NUP43 interactions | 3.30e-04 | 625 | 31 | 6 | int:NUP43 | |
| Interaction | PRKRA interactions | 3.34e-04 | 400 | 31 | 5 | int:PRKRA | |
| Interaction | RTRAF interactions | 3.57e-04 | 222 | 31 | 4 | int:RTRAF | |
| Interaction | KLF9 interactions | 3.89e-04 | 93 | 31 | 3 | int:KLF9 | |
| Interaction | ZCCHC10 interactions | 4.50e-04 | 236 | 31 | 4 | int:ZCCHC10 | |
| Interaction | NIFK interactions | 4.69e-04 | 431 | 31 | 5 | int:NIFK | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr9q34 | 1.36e-03 | 325 | 31 | 3 | chr9q34 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr6q23 | 2.95e-03 | 119 | 31 | 2 | chr6q23 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr6q22 | 3.35e-03 | 127 | 31 | 2 | chr6q22 | |
| GeneFamily | Rho GTPase activating proteins|BCH domain containing | 9.93e-04 | 50 | 17 | 2 | 721 | |
| Coexpression | GSE26030_UNSTIM_VS_RESTIM_TH17_DAY15_POST_POLARIZATION_UP | 1.85e-06 | 175 | 31 | 5 | M8578 | |
| Coexpression | GSE35435_RESTING_VS_IL4_TREATED_MACROPHAGE_UP | 3.56e-06 | 200 | 31 | 5 | M9542 | |
| Coexpression | NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_NEGATIVE | 1.70e-05 | 474 | 31 | 6 | M40991 | |
| Coexpression | NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_DN | 4.68e-05 | 844 | 31 | 7 | M41129 | |
| Coexpression | GSE6674_UNSTIM_VS_PL2_3_STIM_BCELL_DN | 5.02e-05 | 173 | 31 | 4 | M6923 | |
| Coexpression | GSE2935_UV_INACTIVATED_VS_LIVE_SENDAI_VIRUS_INF_MACROPHAGE_DN | 5.85e-05 | 180 | 31 | 4 | M6317 | |
| Coexpression | GSE29949_CD8_NEG_DC_SPLEEN_VS_MONOCYTE_BONE_MARROW_UP | 8.47e-05 | 198 | 31 | 4 | M8404 | |
| Coexpression | GSE40666_WT_VS_STAT1_KO_CD8_TCELL_WITH_IFNA_STIM_90MIN_UP | 8.64e-05 | 199 | 31 | 4 | M9214 | |
| Coexpression | GSE40655_FOXO1_KO_VS_WT_NTREG_UP | 8.81e-05 | 200 | 31 | 4 | M9439 | |
| Coexpression | GSE29164_UNTREATED_VS_CD8_TCELL_TREATED_MELANOMA_DAY7_UP | 8.81e-05 | 200 | 31 | 4 | M8505 | |
| Coexpression | GSE14908_RESTING_VS_HDM_STIM_CD4_TCELL_ATOPIC_PATIENT_UP | 8.81e-05 | 200 | 31 | 4 | M7077 | |
| Coexpression | GSE36078_UNTREATED_VS_AD5_T425A_HEXON_INF_MOUSE_LUNG_DC_UP | 8.81e-05 | 200 | 31 | 4 | M9293 | |
| Coexpression | GSE20366_CD103_KLRG1_DP_VS_DN_TREG_DN | 8.81e-05 | 200 | 31 | 4 | M4343 | |
| Coexpression | SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP | 1.04e-04 | 404 | 31 | 5 | M19488 | |
| Coexpression | NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN | 1.26e-04 | 680 | 31 | 6 | M41089 | |
| Coexpression | GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP | 1.29e-04 | 83 | 31 | 3 | M15537 | |
| Coexpression | NELSON_RESPONSE_TO_ANDROGEN_UP | 1.29e-04 | 83 | 31 | 3 | M13903 | |
| Coexpression | HALLMARK_ANDROGEN_RESPONSE | 2.31e-04 | 101 | 31 | 3 | M5908 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.17e-04 | 169 | 31 | 3 | 0867528101767fc65e93b3561480bf830c50368d | |
| ToppCell | COVID-19_Mild-Neu_2|COVID-19_Mild / 5 Neutrophil clusters in COVID-19 patients | 2.28e-04 | 172 | 31 | 3 | f5fd08b42c002d4693646b27e7b708eceb49524f | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_SST_CXCL14|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.56e-04 | 179 | 31 | 3 | c7afbd10072d36a35cd20ae73670d76b9cefd22d | |
| ToppCell | PBMC-Severe-Lymphocyte-T/NK-CD8+_T-MAIT-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.69e-04 | 182 | 31 | 3 | f30e5a21b49f30b82e2b6f1fd2daefd805a40083 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.69e-04 | 182 | 31 | 3 | 7dc61e901428cea04f00ebb0939a44d21a6145c6 | |
| ToppCell | COVID-19_Severe-Lymphoid_T/NK-MAIT|COVID-19_Severe / Disease group, lineage and cell class | 2.69e-04 | 182 | 31 | 3 | 19045db5c726c06ec6e4feb4311633c8164ddb3c | |
| ToppCell | PBMC-Severe-Lymphocyte-T/NK-CD8+_T-MAIT|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.69e-04 | 182 | 31 | 3 | 1444cdc4522a70a40d697ccadf54cf26d327ade0 | |
| ToppCell | PBMC-Severe-Lymphocyte-T/NK-CD8+_T-MAIT-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.69e-04 | 182 | 31 | 3 | cccac9f85825f4e310b86e37ee6320769a670501 | |
| ToppCell | PBMC-Severe-Lymphocyte-T/NK-CD8+_T-MAIT|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.69e-04 | 182 | 31 | 3 | 49eced222e8f90c2b59bcc7d56b62c3e703fcce5 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.74e-04 | 183 | 31 | 3 | ff751a97466807bf04b5a0740138c61e298cd1fc | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_MHC-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.87e-04 | 186 | 31 | 3 | c7e2134454ab5d0885050dd1bb3c3bd15bf497ac | |
| ToppCell | droplet-Bladder-nan|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.92e-04 | 187 | 31 | 3 | 663991a8afe652e92363b64bcbd68c14d0307f0e | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group | 3.01e-04 | 189 | 31 | 3 | a48df46274d51e84ffb40264646de7346104efb9 | |
| ToppCell | droplet-Large_Intestine-COLON_PROXIMAL-30m-Epithelial-Lgr5-_amplifying_undifferentiated_cell|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.05e-04 | 190 | 31 | 3 | 36e83995021ba16690f84e2077a9e8baec547d05 | |
| ToppCell | Severe-Lymphoid-NK-Treg|Severe / Condition, Lineage, Cell class and cell subclass | 3.05e-04 | 190 | 31 | 3 | e67803bf55a3f8e47a69ff1829c9100f870d7527 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_with-steroid-Lymphocytic|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.05e-04 | 190 | 31 | 3 | 373629dde5eda722424c5e6087763f0c5db67cf4 | |
| ToppCell | droplet-Large_Intestine-COLON_PROXIMAL-30m-Epithelial-epithelial_cell_of_large_intestine|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.05e-04 | 190 | 31 | 3 | d26be9e1b676f750e716b91ebc3598fac3735612 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.05e-04 | 190 | 31 | 3 | 0a944da2aaaef9289b2a4ffe360b0338724fd59b | |
| ToppCell | saliva-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.10e-04 | 191 | 31 | 3 | 6e1d00404d795ec7cf60f685e42e4ad9a16ac596 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.10e-04 | 191 | 31 | 3 | f158e393976b685b896a41871bda1ab65a8b58f5 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.10e-04 | 191 | 31 | 3 | 1ecd9849d14d5ebf3daf610e83fb50820cafd3ed | |
| ToppCell | 390C-Myeloid-Mast_cell-|390C / Donor, Lineage, Cell class and subclass (all cells) | 3.10e-04 | 191 | 31 | 3 | 88bcd0b85b2112cef15c9e44d1429f9fba4a3400 | |
| ToppCell | 390C-Myeloid-Mast_cell|390C / Donor, Lineage, Cell class and subclass (all cells) | 3.10e-04 | 191 | 31 | 3 | c1517ea7b10a7f732725b4c0224fbfecae80d18b | |
| ToppCell | ASK452-Immune-Mast_cell|Immune / Donor, Lineage and Cell class of Lung cells from Dropseq | 3.15e-04 | 192 | 31 | 3 | 8269b88ff6073a908f547fcc7c5941f2e8289694 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c06-NR4A2|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.15e-04 | 192 | 31 | 3 | 348d39da3016dc6dbfa65d108e5def35aa7f19dd | |
| ToppCell | 343B-Myeloid-Macrophage-FABP4+_Macrophage_2|Macrophage / Donor, Lineage, Cell class and subclass (all cells) | 3.25e-04 | 194 | 31 | 3 | 6cf9d59aec8dd18fa2fc1652ddd0f5ef1f24bcb6 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.25e-04 | 194 | 31 | 3 | e3d63874111d1e8da3977329426e4dcf68d6de87 | |
| ToppCell | Hippocampus-Neuronal|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 3.25e-04 | 194 | 31 | 3 | 8aeb347b3024354c9505f4f0fddf0b843489dc6b | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.25e-04 | 194 | 31 | 3 | 449ce4167d64c170d914e0250f739eabedcf915d | |
| ToppCell | Children_(3_yrs)-Immune-alveolar_macrophage_(MARCO_positive)-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.30e-04 | 195 | 31 | 3 | 9d649ac7d2af313481069c95349efc0c68449e2b | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.30e-04 | 195 | 31 | 3 | ed5f772c82d4dfd1c8735224446ec9feae3fb8c2 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.30e-04 | 195 | 31 | 3 | 5c86fddd6d0530beecf45ea5ba6b823123847696 | |
| ToppCell | 390C-Myeloid|390C / Donor, Lineage, Cell class and subclass (all cells) | 3.34e-04 | 196 | 31 | 3 | 5b690062db162e9ddd1a32b1be4d10f5f99c9407 | |
| ToppCell | ILEUM-inflamed-(7)_Endothelial_cell-(7)_CD36+_endothelial_cells|(7)_Endothelial_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 3.40e-04 | 197 | 31 | 3 | 66339b5aae3952f5c484c9dcb0cfb4fbd828d4cb | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.40e-04 | 197 | 31 | 3 | ef2d1f56acd0be43e69bba7f73f6909ba87f1cb3 | |
| ToppCell | COVID-19_Mild|World / Disease group, lineage and cell class | 3.40e-04 | 197 | 31 | 3 | 5c33454b10023decd2f5ccda9229b6512659711e | |
| ToppCell | nucseq-Immune-Immune_Myeloid-IM|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.40e-04 | 197 | 31 | 3 | 6f41c8f815851968849428ec92c16745bd01a3fb | |
| ToppCell | H1299-infected-SARSCoV2|infected / Cell line, Condition and Strain | 3.40e-04 | 197 | 31 | 3 | 0fa3e4cf93e77d78b1f97b906c5b13ca741ae17e | |
| ToppCell | nucseq-Immune-Immune_Myeloid-IM-IM|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.40e-04 | 197 | 31 | 3 | 304044ace926943b8eb588f686ecbe5d1689a809 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.40e-04 | 197 | 31 | 3 | f807d8cd377ee58c02be7f71b39cd227f6b4f5df | |
| ToppCell | BL-critical-LOC-Lymphoid|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 3.45e-04 | 198 | 31 | 3 | 1c0227e58a64c0bf509bfb9578fb91277316b120 | |
| ToppCell | (11)_FOXN4+-(2)_GFP_FOXI1|(11)_FOXN4+ / shred by cell type by condition | 3.45e-04 | 198 | 31 | 3 | 76d40b8c2f8399725b3a62ee2ae0896559cf91eb | |
| ToppCell | moderate-Lymphoid-CTL|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 3.45e-04 | 198 | 31 | 3 | 0a868098b1ee4b28b2149ed766acb09e9c0ce14c | |
| ToppCell | PBMC-Mild|PBMC / Location, Disease Group, Cell group, Cell class (2021.03.09) | 3.45e-04 | 198 | 31 | 3 | 44417089b62056269cac38d3134ff209c05b7007 | |
| ToppCell | (1)_T_cell-(11)_Activated_CD4_T|(1)_T_cell / shred on Cell_type and subtype | 3.45e-04 | 198 | 31 | 3 | 4b9ad91342f622c63e476d4f6a0ae5bf282a7ef5 | |
| ToppCell | PBMC-Mild|PBMC / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.45e-04 | 198 | 31 | 3 | 28ef3fc4c17dcb765537b75917f7db78baa522db | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.45e-04 | 198 | 31 | 3 | 8ab40fae14fe02e39bc8c8da187a5cd60c787643 | |
| ToppCell | mild-CD4+_T_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.50e-04 | 199 | 31 | 3 | 3e4baaf4ee23f257d821194468102c00a8ad2f21 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl-Z|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.50e-04 | 199 | 31 | 3 | e225c1bfc55947c30e7948be851daea04975efa5 | |
| ToppCell | (10)_Ciliated-(2)_GFP_FOXI1|(10)_Ciliated / shred by cell type by condition | 3.50e-04 | 199 | 31 | 3 | 61b1ed2db71b96157b92b7535d1955a4033098da | |
| ToppCell | Healthy/Control|World / Disease group and Cell class | 3.50e-04 | 199 | 31 | 3 | 2623c42b3e79e401a485879b52e8bbcbc581544d | |
| ToppCell | T_cells-CCR7+_T_cells|T_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 3.50e-04 | 199 | 31 | 3 | 467820d6abe3024d9d655b9672c2f9cdc1303db3 | |
| ToppCell | (03)_KRT6B+-(2)_GFP_FOXI1|(03)_KRT6B+ / shred by cell type by condition | 3.50e-04 | 199 | 31 | 3 | c425e7975f492ed5cfcca022248adb627e1d27d4 | |
| ToppCell | 5'-Adult|5' / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.50e-04 | 199 | 31 | 3 | 8b7b1fcea9a06522fdfab85d0dfd33010ae96d75 | |
| ToppCell | (02)_MMP9/10+-(2)_GFP_FOXI1|(02)_MMP9/10+ / shred by cell type by condition | 3.50e-04 | 199 | 31 | 3 | 18a7f9ced4364f45b184bd529f32ef02c27779d3 | |
| ToppCell | Frontal_cortex-Neuronal|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 3.50e-04 | 199 | 31 | 3 | f88039d862f3bfa01dc39d2de4f3f548dc5a0e61 | |
| ToppCell | mild-CD4+_Tcm|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.50e-04 | 199 | 31 | 3 | 06c8a0e39f7a33736548f04a5e2263334c8541cf | |
| ToppCell | Striatum-Neuronal|Striatum / BrainAtlas - Mouse McCarroll V32 | 3.55e-04 | 200 | 31 | 3 | c888fd487990cad482a4ca47601cdebc0ca3f3ce | |
| ToppCell | severe-MAIT|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.55e-04 | 200 | 31 | 3 | 1daf43f1bdd49585dce5e957820554d7f3c1bd4a | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Lymphoid|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.55e-04 | 200 | 31 | 3 | e642b3e25b2884b2bc6114683fa7ac39d6559bf8 | |
| ToppCell | severe|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.55e-04 | 200 | 31 | 3 | accc618d6b960bff30cb531c1226295bfc8650f6 | |
| ToppCell | COVID-19-COVID-19_Severe-Lymphocyte-T/NK-MAIT|COVID-19_Severe / Disease, condition lineage and cell class | 3.55e-04 | 200 | 31 | 3 | b8cfccecff9900aee323c40e771c94e560b8c488 | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST-BAGE2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 3.55e-04 | 200 | 31 | 3 | 26f07d271e984f375145e4c10528fba44a5811e1 | |
| ToppCell | PBMC-Severe-Lymphocyte-T/NK|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 3.55e-04 | 200 | 31 | 3 | 73b91cb66c375b44e852404a4a445cf2b9595aee | |
| ToppCell | severe-MAIT|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.55e-04 | 200 | 31 | 3 | 8a849d0ef244aa2666da2d31bd0731fb04e40911 | |
| ToppCell | COVID-19|World / Disease, condition lineage and cell class | 3.55e-04 | 200 | 31 | 3 | 7dec470c379cd89f05a0f37c8628b21f136e52f0 | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST-BAGE2-L1-2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 3.55e-04 | 200 | 31 | 3 | c3637827ceba16b0d7956c280dd2ddbc8b1ba55e | |
| ToppCell | COVID-19-Myeloid-MoAM2,_CCL18|Myeloid / Condition, Lineage and Cell class | 3.55e-04 | 200 | 31 | 3 | a60346c5ea7a3dae1ad3c5dc6c6eca65b64c6888 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Lymphoid-CD4/CD8|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.55e-04 | 200 | 31 | 3 | bb05d2d10c924202f78fa1bd271f60cbbf224108 | |
| ToppCell | metastatic_Brain-Myeloid_cells-mo-Mac|Myeloid_cells / Location, Cell class and cell subclass | 3.55e-04 | 200 | 31 | 3 | bfb54a8ce44caf01083c6567b236395c6ee1d47a | |
| ToppCell | Sigmoid-T_cell-Activated_CD4_T|T_cell / Region, Cell class and subclass | 3.55e-04 | 200 | 31 | 3 | 9c21e6b8d4f8e526950adacf9cc45a5e86d81c1f | |
| ToppCell | severe-CD4+_Tcm|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.55e-04 | 200 | 31 | 3 | e83558090a079dd9e40e0d3b5d9917fbd2695ec4 | |
| ToppCell | mild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.55e-04 | 200 | 31 | 3 | 12f1685ce8f218433068e090c9d839cd5a1910bf | |
| ToppCell | COVID-19_Severe-Lymphoid_T/NK|COVID-19_Severe / Disease group, lineage and cell class | 3.55e-04 | 200 | 31 | 3 | 9fc818bf5c9133fc2fece47980e71fd3f8603558 | |
| ToppCell | PBMC-Severe-Lymphocyte-T/NK|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.55e-04 | 200 | 31 | 3 | f1c8780d64b58b6fb84fffbc27f0ad337b1a6e56 | |
| Drug | Captopril [62571-86-2]; Down 200; 17.2uM; PC3; HT_HG-U133A | 4.09e-06 | 179 | 31 | 5 | 4585_DN | |
| Disease | leptin measurement | 3.29e-03 | 81 | 31 | 2 | EFO_0005000 | |
| Disease | body surface area | 4.41e-03 | 643 | 31 | 4 | EFO_0022196 | |
| Disease | thyroid stimulating hormone measurement | 4.66e-03 | 323 | 31 | 3 | EFO_0004748 | |
| Disease | obesity (is_marker_for) | 5.06e-03 | 101 | 31 | 2 | DOID:9970 (is_marker_for) | |
| Disease | Mental Retardation, Psychosocial | 9.37e-03 | 139 | 31 | 2 | C0025363 | |
| Disease | Profound Mental Retardation | 9.37e-03 | 139 | 31 | 2 | C0020796 | |
| Disease | Mental deficiency | 9.37e-03 | 139 | 31 | 2 | C0917816 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| KKYHKKKKIMLSDEM | 126 | Q96M60 | |
| AHLSKKEKKKLKKQM | 251 | Q8NE71 | |
| KKLLAHKNSMKKKAK | 281 | Q8IUX8 | |
| SMSHKKSKKKSKKHK | 456 | O00472 | |
| KSKKKSKKHKEKDQI | 461 | O00472 | |
| KKKKKKSKMDRHGND | 451 | Q8WY36 | |
| KTHSDLMREKKKLKK | 21 | Q8N157 | |
| LKEEKLHAKKMKLTK | 126 | Q9H175 | |
| KKMDKEGKTLKKHKL | 641 | Q6UB98 | |
| AKKKHLDKKRKLKEM | 821 | Q14692 | |
| EKAAKKKSKHKKSKD | 666 | Q3YEC7 | |
| KKSKHKKSKDKEEGK | 671 | Q3YEC7 | |
| SHKKLKLTKMRAKKK | 671 | Q5HYC2 | |
| AKACEEKKKKHKMTA | 276 | P14222 | |
| KKHSKEKKGSKKDIK | 496 | P35663 | |
| IALKMEADEKKKKKK | 366 | Q13601 | |
| KKKKDKEKHKEKRHS | 326 | Q9UGU5 | |
| DKKMQKKMKKAHKKM | 106 | Q9NZ81 | |
| KKMKKAHKKMHKHQK | 111 | Q9NZ81 | |
| KEKKEKTEKKFDHSK | 336 | Q8NFC6 | |
| LHKKHTKKMDKTAKL | 521 | Q9GZR7 | |
| GMKHVKKEKAEKLEK | 111 | O75880 | |
| EKKKWKDLKLMKKLE | 31 | Q5T280 | |
| KEHKETAKKKKKLKN | 271 | Q9UHY8 | |
| IAAKKKMKKHKNKSE | 2741 | O75691 | |
| KKAILKKKEEKHIMS | 131 | O00141 | |
| ELDDKKMKKKTHKVK | 1221 | Q13017 | |
| KMKKKTHKVKEDKKQ | 1226 | Q13017 | |
| THKVKEDKKQKKKTK | 1231 | Q13017 | |
| KHLKRKAMTKKKELT | 136 | Q00059 | |
| GEKIMHDVIKKVKKK | 11 | P61764 | |
| HKKDKRAMKKLLKKM | 541 | Q8N392 | |
| EKKATHKEKIEKKEK | 181 | Q13061 | |
| KVHKKKMEELKKYIE | 251 | Q2TB10 | |
| HDPDKKKMKLKVKKS | 301 | Q92664 | |
| VHKKDKKYKCMVCKK | 771 | Q96DT7 | |
| ELEKMEKKKRKHEKK | 196 | A6NJT0 |